It was estimated that in the period 2016-2019, around 16 percent of children and adolescents aged 3 to 17 years in the state of Louisiana had been diagnosed with attention deficit hyperactivity disorder (ADHD) at some point in their life. This statistic shows the percentage of children and adolescents in the United States who had ever been diagnosed with ADHD as of 2016-2019, by state.

From 2020 to 2022, around 18 percent of children in the United States aged 12 to 17 years with a family income less than 100 percent the federal poverty level (FPL) had ADHD, compared to 13 percent of children at this age who were from households with a family income of 200 percent of the FPL or more. This statistic displays the percentage of children in the U.S. aged 5 to 17 years who had ever been told by a doctor or health professional they had attention deficit hyperactivity disorder (ADHD) from 2020 to 2022, by age and family income.

This statistic shows the percentage of children in the U.S. with attention deficit hyperactivity disorder (ADHD) from 1997 to 2018. In 2018, around 9.8 percent of children in the U.S. had been diagnosed with ADHD, compared to 5.5 percent in 1997.

Site abbreviations: Peking University (Peking), Kennedy Krieger Institute (KKI), NeuroIMAGE (NI), New York University (NYU), Oregon Health and Science University (Oregon), University of Pittsburgh (Pitt), Washington University in St. Louis (WashU).

From 2020 to 2022, around **** percent of children in the United States aged 12 to 17 years had ADHD. This statistic displays the percentage of children in the U.S. aged 5 to 17 years who had ever been told by a doctor or health professional they had attention deficit hyperactivity disorder (ADHD) from 2020 to 2022, by age.

Attention deficit hyperactivity disorder (ADHD) is defined by the World Health Organization as being characterised by a persistent pattern of inattention and/or hyperactivity-impulsivity that has a direct negative impact on academic, occupational, or social functioning, the level of which is outside the limits of normal variation expected for age and level of intellectual functioning. Historically there has been no specific data publicly available about people with ADHD. The ADHD data improvement plan highlighted the need to make use of and publish existing data held by NHS England in this area whilst also working to improve data quality. In this initial publication data is available on the following areas: estimated prevalence of ADHD, the number of people who may be waiting for ADHD assessments, including how long they have been waiting. A full list of measures currently contained in the publication is published in a data dictionary alongside each release

The global Attention Deficit Hyperactivity Disorder (ADHD) market is experiencing steady growth, with a market size of $12.59 billion in 2025 and a projected Compound Annual Growth Rate (CAGR) of 3.2% from 2025 to 2033. This growth is driven by several factors, including the increasing prevalence of ADHD diagnoses, particularly among children and adolescents, heightened awareness of the condition, and the continuous development of more effective and tolerable treatment options. Improved diagnostic tools and greater access to healthcare, especially in developing economies, are also contributing to market expansion. While the market faces some restraints such as concerns about the long-term effects of stimulant medications and the potential for misuse, the overall trajectory points towards significant market expansion. The growing adoption of non-stimulant medications and digital therapeutics for ADHD management is expected to further fuel this growth in the coming years. Pharmaceutical companies such as Eli Lilly, Novartis, Takeda, Pfizer, GlaxoSmithKline, Mallinckrodt, Hisamitsu, Johnson & Johnson, and Purdue Pharma are key players vying for market share through research, development, and strategic marketing initiatives. The competitive landscape is characterized by both established pharmaceutical giants and emerging players focusing on innovative treatment approaches. The market is segmented based on medication type (stimulants vs. non-stimulants), treatment setting (hospital, clinic, home), and patient demographics (adult vs. pediatric). Although regional data is unavailable, market trends suggest that North America and Europe currently hold substantial market shares, driven by higher healthcare expenditure and greater awareness of ADHD. However, growth opportunities are anticipated in emerging markets like Asia-Pacific and Latin America as healthcare infrastructure improves and diagnostic capabilities expand. Further research and development into personalized medicine tailored to specific ADHD subtypes could further reshape the market landscape in the long term.

Background: Previous studies have reported a high prevalence of attention deficit hyperactivity disorder (ADHD) among people living in detention (PLD) corresponding to a five- to ten-fold increase compared to the general population. Our main study objective was to provide an updated ADHD prevalence rate for PLD, including PLD in psychiatric units. Sub-objectives included (i) comparing different ways of assessing ADHD, including DSM-5 criteria and (ii) identifying which types of PLD are more likely to have ADHD.Methods: We conducted a systematic review and meta-analysis following the PRISMA guidelines and the MOOSE checklist. PubMed/Medline, PsycINFO, and Web of Sciences were searched combining “ADHD” and “prison” keywords and synonyms for articles published between January 1, 1966 and January 2, 2018. Potential sources of variation to the meta-analytic ADHD prevalence rate were investigated using meta-regressions and subgroups analyses.Results: The meta-analysis pooled 102 original studies including 69,997 participants. The adult ADHD prevalence rate was 26.2% (95% confidence interval: 22.7–29.6). Retrospective assessments of ADHD in childhood were associated with an increased prevalence estimate (41.1, 95% confidence interval: 34.9–47.2, p < 0.001). There was no significant difference in the prevalence estimate between screenings and clinical interviews in adulthood. Only three studies used the DSM-5 definition of ADHD and results were non-significantly different with other DSM versions. We found no difference according to participants' characteristics.Conclusion: Our results confirmed the high prevalence rate of ADHD among PLD, corresponding to a five-fold increase compared to the general population. In light of such high ADHD prevalence, our results reinforce the importance of addressing this critical public health issue by (i) systematically offering ADHD screening and diagnosis to all individuals entering detention, and (ii) delivering treatment, monitoring, and care for ADHD during and after detention. These strategies may help reduce recidivism and reincarceration, as well as violence in detention settings, in addition to improving the health and wellbeing of people living in detention. Additionally, our study suggests that using screening scales may be a reliable way of assessing ADHD, although caution is needed because a complete evaluation by an experienced clinician is required to provide a formal diagnosis.

Research found that adults with attention deficit hyperactivity disorder (ADHD) have more problems with financial decision-making than healthy controls. The present study investigates the impact of symptoms of ADHD on impulsive buying and the use of financial decision styles. Furthermore, the influence of personality, symptoms of depression and demographics on the association between ADHD and these aspects of financial decision-making is evaluated. A community sample of 1292 participants (age range 18–93 years, 45.4% male) completed questionnaires related to ADHD, impulsive buying, financial decision styles, personal financial situation, depression and personality. Four groups were formed based on self-reported ADHD symptoms: an ‘ADHD’ group (n=45), an ‘Adult-only ADHD’ group (n=57), a ‘Subthreshold ADHD’ group (n=162) and a ‘No ADHD’ group (n=265). Groups were compared using ANOVA and chi-square tests. Furthermore, multiple regression analyses in the complete sample were employed to examine the association between ADHD and financial decision-making. The ADHD and Adult-only ADHD groups reported significantly more impulsive buying, used more often an avoidant or spontaneous decision style and less often saved money compared to the No ADHD group. Regression analyses revealed that impulsive buying and financial decision styles were not significantly associated with ADHD symptoms when controlling for personality, symptoms of depression and demographics. The present study confirms previous research on adults with ADHD by indicating more impulsive buying and a more frequent use of disadvantageous financial decision styles (i.e., avoidant and spontaneous styles) in individuals with an elevated number of current symptoms of ADHD compared to individuals without symptoms of ADHD. Personality and demographic variables were found to be related to both impulsive buying and the use of specific financial decision styles and might be of influence on the association between impulsive buying, the use of financial decision styles and ADHD.

The aim of this publication is to provide information about the key differences in healthcare between people with a learning disability and those without. It contains aggregated data on key health issues for people who are recorded by their GP as having a learning disability, and comparative data about a control group who are not recorded by their GP as having a learning disability. Eight new indicators were introduced in the 2023-24 reporting year for patients with and without a recorded learning disability. These relate to: • Patients treated with melatonin • Gender breakdown for attention deficit hyperactivity disorder (ADHD) • Anxiety prevalence Six indicators have been removed from the 2023-24 reporting year relating to: • Kidney disease • Epilepsy • Seizure frequency More information on these changes can be found in the Data Quality section of this publication. Data has been collected from participating practices using EMIS and Cegedim Healthcare Systems GP systems.

From 2020 to 2022, around 11 percent of children in the United States aged 5 to 17 years had ADHD. This statistic displays the percentage of children in the U.S. aged 5 to 17 years who had ever been told by a doctor or health professional they had attention deficit hyperactivity disorder (ADHD) from 2020 to 2022, by gender.

Attention deficit hyperactivity disorder (ADHD) is highly prevalent childhood-onset neurodevelopment disorder. Several clinical tools are used for ADHD diagnosis such as behavior rating scales, intelligence tests, severity, and dysfunction scales. However, these methods depend to the experience and training of physician increasing human error. DICOM Images using Magnetic Resonance Imaging (MRI) provides quantitative result such as fractional anisotropy or the number of tracts that could be helpful to support ADHD diagnosis.

The data set being sent is made up of two data sets. One data set is composed of children with ADHD and the other data set is composed of healthy control children. All MRI studies were performed on 1.5 T Philips Intera Achieva scanner (Philips, Inc., Netherlands) using an eight channel SENSE head-coil, Gradient Coils NOVA, (Copley 271 Dual, slew rate 80mT/m/ms, peak amplitude 120mT/m). Diffusion weighted images were obtained covering the entire brain, with an axial EPI sequence with settings TR = 9491s, TE = 75 ms, FOV = 230 mm × 230 mm, matrix 124 × 124, 15 non-collinear directions (b-value 800 s/mm2) with fat suppression. Scans were acquired in the supine position and with the eyes closed (but always awake). Attention deficit hyperactivity disorder (ADHD) is highly prevalent childhood-onset neurodevelopment disorder. Several clinical tools are used for ADHD diagnosis such as behavior rating scales, intelligence tests, severity, and dysfunction scales. However, these methods depend to the experience and training of physician increasing human error. DICOM Images using Magnetic Resonance Imaging (MRI) provides quantitative result such as fractional anisotropy or the number of tracts that could be helpful to support ADHD diagnosis.

Background: Previous studies have reported a high prevalence of attention deficit hyperactivity disorder (ADHD) among people living in detention (PLD) corresponding to a five- to ten-fold increase compared to the general population. Our main study objective was to provide an updated ADHD prevalence rate for PLD, including PLD in psychiatric units. Sub-objectives included (i) comparing different ways of assessing ADHD, including DSM-5 criteria and (ii) identifying which types of PLD are more likely to have ADHD.Methods: We conducted a systematic review and meta-analysis following the PRISMA guidelines and the MOOSE checklist. PubMed/Medline, PsycINFO, and Web of Sciences were searched combining “ADHD” and “prison” keywords and synonyms for articles published between January 1, 1966 and January 2, 2018. Potential sources of variation to the meta-analytic ADHD prevalence rate were investigated using meta-regressions and subgroups analyses.Results: The meta-analysis pooled 102 original studies including 69,997 participants. The adult ADHD prevalence rate was 26.2% (95% confidence interval: 22.7–29.6). Retrospective assessments of ADHD in childhood were associated with an increased prevalence estimate (41.1, 95% confidence interval: 34.9–47.2, p < 0.001). There was no significant difference in the prevalence estimate between screenings and clinical interviews in adulthood. Only three studies used the DSM-5 definition of ADHD and results were non-significantly different with other DSM versions. We found no difference according to participants' characteristics.Conclusion: Our results confirmed the high prevalence rate of ADHD among PLD, corresponding to a five-fold increase compared to the general population. In light of such high ADHD prevalence, our results reinforce the importance of addressing this critical public health issue by (i) systematically offering ADHD screening and diagnosis to all individuals entering detention, and (ii) delivering treatment, monitoring, and care for ADHD during and after detention. These strategies may help reduce recidivism and reincarceration, as well as violence in detention settings, in addition to improving the health and wellbeing of people living in detention. Additionally, our study suggests that using screening scales may be a reliable way of assessing ADHD, although caution is needed because a complete evaluation by an experienced clinician is required to provide a formal diagnosis.

A grassroots initiative dedicated to accelerating the scientific community''''s understanding of the neural basis of ADHD through the implementation of open data-sharing and discovery-based science. They believe that a community-wide effort focused on advancing functional and structural imaging examinations of the developing brain will accelerate the rate at which neuroscience can inform clinical practice. The ADHD-200 Global Competition invited participants to develop diagnostic classification tools for ADHD diagnosis based on functional and structural magnetic resonance imaging (MRI) of the brain. Applying their tools, participants provided diagnostic labels for previously unlabeled datasets. The competition assessed diagnostic accuracy of each submission and invited research papers describing novel, neuroscientific ideas related to ADHD diagnosis. Twenty-one international teams, from a mix of disciplines, including statistics, mathematics, and computer science, submitted diagnostic labels, with some trying their hand at imaging analysis and psychiatric diagnosis for the first time. The data for the competition was provided by the ADHD-200 Consortium. Consortium members from institutions around the world provided de-identified, HIPAA compliant imaging datasets from almost 800 children with and without ADHD. A phenotypic file including all of the test set subjects and their diagnostic codes can be downloaded. Winner is presented. The ADHD-200 consortium included: * Brown University, Providence, RI, USA (Brown) * The Kennedy Krieger Institute, Baltimore, MD, USA (KKI) * The Donders Institute, Nijmegen, The Netherlands (NeuroImage) * New York University Medical Center, New York, NY, USA (NYU) * Oregon Health and Science University, Portland, OR, USA (OHSU) * Peking University, Beijing, P.R.China (Peking 1-3) * The University of Pittsburgh, Pittsburgh, PA, USA (Pittsburgh) * Washington University in St. Louis, St. Louis, MO, USA (WashU)

Supplementary data for a Masters study titled 'An exploration of subjective well-being in children and adolescents with ADHD in South Africa during the Covid-19 pandemic'. The Excel spreadsheet is made up of quantitative data from 376 respondents in the study. It includes demographic data icluding home language, province of residence, type and category of school of the children and adolescents). The data collected include the responses of each respondent on the EPOCH wellbeing scale which was used.

Ce jeu de données contient les stratégies de recherche pour PubMed, Medline (Ovid), Embase (Ovid), All EBM reviews (Ovid), and PsycInfo (Ovid). Quand on les exécute dans leurs bases de données respectives, ces stratégies repêchent les articles sur, inclusivement, les concepts de TDAH, de psychothérapie, de télémédecine et d'adolescent Le nombre de résultats et les stratégies de recherche pour chaque base de données sont indiqués dans le fichier rtf. La date indiquée dans cette description est la date à laquelle la recherche a été effectuée. (2023-07-31)

Odds ratio statistics for ADHD outcomes and chemical exposures. This dataset is associated with the following publication: Nilsen, F., and N. Tulve. A systematic review and meta-analysis examining the interrelationships between chemical and non-chemical stressors and inherent characteristics in children with ADHD. ENVIRONMENTAL RESEARCH. Elsevier B.V., Amsterdam, NETHERLANDS, 180: 108884, (2020).

This dataset consists of survey responses from 57 African American parents/caregivers whose child was receiving care for ADHD in a university-affiliated pediatric primary care unit. The 47 item questionnaire entitled Attitudes, Satisfaction, Knowledge, and Medication Experiences (ASK-ME) was developed by the primary author to assess views of stimulant medication for ADHD. In addition to demographic information, the dataset includes treatment characteristics, whether or not the child received counseling, and responses to 7 items specifically related to attitude toward medication. A copy of the survey is available from Dr. Susan dosReis upon request.